Arvinas Inc (ARVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arvinas Inc (ARVN) has a cash flow conversion efficiency ratio of -0.070x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-30.40 Million) by net assets ($433.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Arvinas Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Arvinas Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ARVN current and long-term liabilities for a breakdown of total debt and financial obligations.
Arvinas Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arvinas Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Advanced Nano Products Co. Ltd
KQ:121600
|
0.027x |
|
MTY Food Group Inc
TO:MTY
|
0.048x |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
0.063x |
|
Jinling Pharmaceutical Co Ltd
SHE:000919
|
0.015x |
|
Bank Bukopin Tbk
JK:BBKP
|
-0.131x |
|
BridgeBio Oncology Therapeutics, Inc.
NASDAQ:BBOT
|
-0.103x |
|
Fujian Rongji Software Co Ltd
SHE:002474
|
-0.005x |
|
Sichuan Kexin Mechanic Electric
SHE:300092
|
0.019x |
Annual Cash Flow Conversion Efficiency for Arvinas Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Arvinas Inc from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Arvinas Inc (ARVN) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $433.90 Million | $-273.80 Million | -0.631x | -36.69% |
| 2024-12-31 | $561.70 Million | $-259.30 Million | -0.462x | +12.40% |
| 2023-12-31 | $660.00 Million | $-347.80 Million | -0.527x | -8.84% |
| 2022-12-31 | $564.90 Million | $-273.50 Million | -0.484x | -167.66% |
| 2021-12-31 | $781.70 Million | $559.40 Million | 0.716x | +612.02% |
| 2020-12-31 | $642.20 Million | $-89.76 Million | -0.140x | +22.01% |
| 2019-12-31 | $226.69 Million | $-40.63 Million | -0.179x | -51.97% |
| 2018-12-31 | $136.67 Million | $-16.12 Million | -0.118x | -100.57% |
| 2017-12-31 | $245.87K | $5.11 Million | 20.796x | +2675.61% |
| 2016-12-31 | $24.03 Million | $-19.40 Million | -0.807x | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more